A pilot first in human study of Thymosin-beta-4 in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI) or heart attack

Trial Profile

A pilot first in human study of Thymosin-beta-4 in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI) or heart attack

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 22 Jun 2016 New trial record
    • 14 Jun 2016 According to a RegeneRx Biopharmaceuticals media release, results from this study were published in International Society for Cellular Therapy.
    • 14 Jun 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top